# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January, 2022

Commission File Number 001-35463

# **Taro Pharmaceutical Industries Ltd.**

(Translation of registrant's name into English)

**14 Hakitor Street, Haifa Bay 2624761, Israel** (Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):



Taro Pharmaceutical Industries Ltd. c/o Taro Pharmaceuticals U.S.A., Inc. Three Skyline Drive Hawthorne, New York 10532 (NYSE: TARO)

## FOR IMMEDIATE RELEASE

CONTACTS: William J. Coote VP, Chief Financial Officer (914) 345-9001 William.Coote@taro.com

### **TARO PROVIDES RESULTS FOR DECEMBER 31, 2021**

**Hawthorne, NY, January 27, 2022** — Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today provided unaudited financial results for the quarter and nine months ended December 31, 2021.

## Quarter ended December 31, 2021 Highlights – compared to December 31, 2020

- □ Net sales of \$139.0 million decreased \$1.2 million.
- Gross profit of \$76.0 million increased \$2.8 million, and as a percentage of net sales was 54.7% compared to 52.2%.
- Research and development ("R&D") expenses of \$14.2 million were in line with the prior year quarter.
- Selling, marketing, general and administrative expenses ("SG&A") of \$24.8 million increased \$2.0 million.
- Operating income of \$37.0 million was in line with the prior year quarter, and as a percentage of net sales was 26.6% compared to 25.9%.
- Interest and other financial income of \$2.1 million decreased \$1.9 million, reflecting the lower global interest rate environment.
- Tax expense of \$13.2 million increased \$7.1 million. Excluding the tax impact from certain items related to the settlement and loss contingencies charges taken in prior periods, tax expense increased \$0.2 million with a resulting effective tax rate of 15.8% compared to 15.6%.
- Net income attributable to Taro was \$26.3 million compared to \$32.9 million, resulting in diluted earnings per share of \$0.70 compared to \$0.86.

## Nine Months ended December 31, 2021 Highlights - compared to December 31, 2020

- □ Net sales of \$418.1 million increased \$17.5 million.
- Gross profit of \$215.8 million decreased \$3.9 million, and as a percentage of net sales was 51.6% compared to 54.8%.
- R&D expenses of \$39.6 million decreased \$3.9 million.
- SG&A of \$72.5 million increased \$3.4 million.
- □ Settlements and loss contingencies of \$61.4 million consist of the additional legal contingency of \$60.0 million (*taken in the first quarter*) related to ongoing multi-jurisdiction civil antitrust matters and \$1.4 million related to the aforementioned global resolution with the Department of Justice ("DOJ") in connection with its investigations into the U.S. generic pharmaceutical industry. In the prior year, settlements and loss contingencies of \$478.9 million consisted of \$418.9 million related to the global resolution with the DOJ in connection with its investigations into the U.S. generic pharmaceutical industry and an additional provision of \$60.0 million related to ongoing multi-jurisdiction civil antitrust matters; however, there can be no assurance as to the ultimate outcome.
- Operating income of \$42.2 million compared to operating loss of \$371.9 million. Excluding the settlement and loss contingencies charges in both periods, operating income was \$103.6 million compared to \$107.0 million and as a percentage of net sales was 24.8% compared to 26.7%.
- Interest and other financial income of \$7.5 million decreased \$9.5 million.

- Tax expense of \$22.0 million increased \$3.4 million. Excluding the impact from the settlement and loss contingencies charges in both periods, tax expense decreased \$3.4 million with a resulting effective tax rate of 13.2% compared to 14.8%.
- □ Net income attributable to Taro was \$30.9 million compared to net loss of \$356.9 million, resulting in diluted earnings (loss) per share of \$0.82 compared to \$(9.33). Excluding the impact from the settlement and loss contingencies charges in both periods, net income was \$99.2 million compared to \$107.1 million, resulting in diluted earnings per share of \$2.64 compared to \$2.80.

### Cash Flow and Balance Sheet Highlights

- Cash flow used in operations was \$200.0 million for the nine months ended December 31, 2021. Excluding the impact from the settlement and loss contingencies charges in both periods, cash flow provided by operations was \$124.6 million compared to \$97.5 million for the nine months ended December 31, 2020.
- □ As of December 31, 2021, cash and cash equivalents and marketable securities (both short and long-term), decreased \$257.4 million to \$1.3 billion from March 31, 2021; reflecting the impact from payments to the DOJ of \$317.6 million as a result of the global resolution with the DOJ in connection with its investigations into the U.S. generic pharmaceutical industry, and share repurchases of \$24.9 million.

Mr. Uday Baldota, Taro's CEO, stated, "Despite the challenging market conditions, particularly in the U.S. generic market, we successfully defended our market share across each business. Our current quarter and nine month performance reflects this. With the intent of ever strengthening the future, we remain focused on high return R&D investments as well as the exploration of new business development opportunities."

## **FDA Approvals and Filings**

The Company recently received approvals from the U.S. Food and Drug Administration ("FDA") for the Abbreviated New Drug Applications ("ANDAs"): Sildenafil Powder for Oral Suspension, 10 mg/mL and Adapalene Gel, USP 0.1%. The Company currently has a total of seventeen ANDAs awaiting FDA approval, including four tentative approvals.

## Taro Pharmaceuticals U.S.A., Inc. ("Taro USA") Signs Settlement Agreement with the Direct Purchaser Plaintiffs

Taro USA entered into a settlement agreement with the direct purchaser class on November 4, 2021, which, if approved by the court, will resolve all claims brought by the direct purchaser class against Taro USA and its parents, affiliates, officers and directors in the *In re: Generic Pharmaceuticals Pricing Antitrust Litigation*. Under the terms of the settlement agreement, Taro USA will pay a maximum of \$67.6 million, subject to a reduction of up to \$8.0 million depending on the decisions of certain class members to opt out of the settlement. The settlement is subject to approval by the court.

The Company cautions that the foregoing financial information is presented on an unaudited basis and is subject to change.

#### \*\*\*\*\*

#### **About Taro**

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com.

#### SAFE HARBOR STATEMENT

The unaudited consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments necessary to present fairly the financial condition and results of operations of the Company. The unaudited consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements included in the Company's Annual Report on Form 20-F, as filed with the SEC.

Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements that do not describe historical facts or that refer or relate to events or circumstances the Company "estimates," "believes," or "expects" to happen or similar language, and statements with respect to the Company's financial performance, availability of financial information, and estimates of financial results and information for fiscal year 2022. Although the Company believes the expectations reflected in such forward-looking statements to be based on reasonable assumptions, it can give no assurances that its expectations will be attained. Factors that could cause actual results to differ include general domestic and international economic conditions, industry and market conditions, changes in the Company's financial position, litigation brought by any party in any court in Israel, the United States, or any country in which Taro operates, regulatory and legislative actions in the countries in which Taro operates, and other risks detailed from time to time in the Company's SEC reports, including its Annual Reports on Form 20-F. Forward-looking statements are applicable only as of the date on which they are made. The Company undertakes no obligations to update, change or revise any forward-looking statement, whether as a result of new information, additional or subsequent developments or otherwise.

\*\*Financial Tables Follow\*\*

#### TARO PHARMACEUTICAL INDUSTRIES LTD. SUMMARY CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

(U.S. dollars in thousands, except share data)

	Quarter Ended December 31,			Nine Months Ended December 31,				
		2021	2020		2021		2020	
Sales, net	\$	138,984	\$	140,145	\$	418,083	\$	400,622
Cost of sales		62,937		66,957		202,293		180,900
Impairment		13				13		
Gross profit		76,034		73,188		215,777		219,722
Operating Expenses:								
Research and development		14,201		14,081		39,648		43,565
Selling, marketing, general and administrative		24,841		22,798		72,501		69,121
Settlements and loss contingencies		26				61,446		478,924
Operating income (loss) *		36,966		36,309		42,182		(371,888)
Financial income, net:								
Interest and other financial income		(2,090)		(4,001)		(7,501)		(16,989)
Foreign exchange expense		544		2,036		555		1,207
Other gain, net		990		863		3,714		2,792
Income (loss) before income taxes		39,501		39,137		52,842		(353,313)
Tax expense		13,188		6,101		21,980		18,545
Net income (loss)		26,313		33,036		30,862		(371,858)
Net income (loss) attributable to non-controlling interest		·		117		·		(14,991)
Net income (loss) attributable to Taro *	\$	26,313	\$	32,919	\$	30,862	\$	(356,867)
Net income (loss) per ordinary share attributable to Taro:								
Basic and Diluted *	\$	0.70	\$	0.86	\$	0.82	\$	(9.33)
Weighted-average number of shares used to compute net income (loss) per share: Basic and Diluted	3	37,584,891		38,254,231	3	37,659,478		38,256,963

May not foot due to rounding.

\* Excluding the settlement and loss contingencies charges of \$61.4 million and \$478.9 million for the nine months ended December 31, 2021 and 2020, Operating income was \$103.6 million and \$107.0 million, Net income attributable to Taro was \$99.2 million and \$107.1 million, and basic and diluted earnings per share was \$2.64 and \$2.80, respectively.

# TARO PHARMACEUTICAL INDUSTRIES LTD. SUMMARY CONSOLIDATED BALANCE SHEETS

(U.S. dollars in thousands)

	<b>December 31,</b> 			December 31, 2020 (audited)		
ASSETS						
CURRENT ASSETS:						
Cash and cash equivalents	\$	318,103	\$	605,177		
Short-term and current maturities of long-term bank deposits		35,573		_		
Marketable securities		433,403		418,480		
Accounts receivable and other:						
Trade, net		224,666		213,539		
Other receivables and prepaid expenses		43,047		53,347		
Inventories		182,446		180,292		
TOTAL CURRENT ASSETS		1,237,238		1,470,835		
Marketable securities		536,348		557,209		
Property, plant and equipment, net		193,995		205,508		
Deferred income taxes		125,659		142,007		
Other assets		29,779		31,314		
TOTAL ASSETS	\$	2,123,019	\$	2,406,873		
LIABILITIES AND SHAREHOLDERS' EQUITY						
CURRENT LIABILITIES:						
Trade payables	\$	43,685	\$	61,166		
Other current liabilities		351,108		615,135		
TOTAL CURRENT LIABILITIES		394,793		676,301		
Deferred taxes and other long-term liabilities		31,672		35,115		
TOTAL LIABILITIES		426,465		711,416		
Taro shareholders' equity		1,696,554		1,703,649		
Non-controlling interest				(8,192)		
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	\$	2,123,019	\$	2,406,873		

## TARO PHARMACEUTICAL INDUSTRIES LTD. SUMMARY CONSOLIDATED STATEMENT OF CASH FLOWS

(Unaudited) (U.S. dollars in thousands)

Cash flows from operating activities: Net income (loss)Z021Z020Adjustments required to reconcile net income (loss) to net cash used in operating activities: Depreciation and amortzation Impairment of long-lived assets11Adjustments required to reconcile net income (loss) to net cash used in operating activities: Depreciation and amortzation Impairment of long-lived assets13 Change in derivative instruments, net(336)(390)(4,288)Effect of change in exchange rate on marketable securities and bank deposits(39)(4,288)Deferred income taxes, net(11,29)(3,635)Increase) in other receivables, net(2,154)(16,454)Decrease (increase) in other receivables, income tax receivables, prepaid expenses and other (10,973)(11,962)(Decrease) increase in trade, income tax, accrued expenses and other payables $7,734$ 2,579Expense from amortization of marketable securities bonds, net(120)(11,210)Investing activities:(19,9366)(5,285)Cash flows from investing activities:(120)(11,210)Purchase of plant, property & equipment, net investing activities(24,934)(3,243)Purchase of reasury stock(24,934)(3,243)Cash flows from financing activities(24,934)(3,243)Effect of exchange rate changes on cash and cash equivalents (Decrease) increase in cash and cash equivalents(200)2,297(Decrease) increase in cash and cash equivalents(24,934)(3,243)Effect of exchange rate changes on cash and cash equiva		Nine Months Ended December 31,				
Net income (loss)\$30.862\$(371,858)Adjustments required to reconcile net income (loss) to net cash used in operating activities: Depreciation and amortization Impairment of long-lived assets13Impairment of long-lived assets13Change in derivative instruments, net(536)(390)Effect of change in exchange rate on marketable securities and bank deposits(39)(4,288)Deferred income taxes, net(11,129)(6,395)Increase in inventories, net(2,154)(16,454)Decrease (increase) in other receivables, income tax receivables, prepaid expenses and other (Decrease) increase in inde, income tax, accrued expenses and other payables(9,973)(11,962)(Decrease) in circase in trade, income tax, accrued expenses and other payables(9,121)(14,210)(Investing activities(120)(11,120)(5,285)Cash flows from investing activities:(120)(11,120)(14,210)Purchase of plant, property & equipment, net(9,121)(14,210)(14,210)Investiment in other intangible assets(17,161)66,122(12,233)Net cash (used in) provided by investing activities(24,934)(3,243)(3,243)Net cash used in financing activities(28,074)39,564(3,243)Effect of exchange rate changes on cash and cash equivalents(200)2,297(28,074)39,564Cash flows from financing activities(24,934)(3,243)(3,243)Net cash used in financing activities(24,934)(3,243) <th></th> <th colspan="2">2021</th> <th colspan="3">2020</th>		2021		2020		
Adjustments required to recordle net income (loss) to net cash used in operating activities:Depreciation and amorization19,24817,337Impairment of long-lived assets13Realized loss on sale of long-lived assets551Change in derivative instruments, net(536)(390)Effect of change in exchange rate on marketable securities and bank deposits(39)(4,288)Deferred increase in inventories, net(11,129)6,395Increase in inventories, net(11,129)6,395Decrease (increase) in other receivables, income tax, accrued expenses and other payables(270,482)4405,233Expense from amorization of marketable securities bonds, net7,7342,579(11,962)Net cash used in operating activities:(120)(117)Investment in other intragible assets(120)(117)Investment in other intragible assets(120)(117)Investment in operating activities:(61,975)45,795Cash flows from financing activities:(24,934)(3,243)Purchase of plant, property & equipment, net(24,934)(3,243)Investment in proceeds from marketable securities, net(17,161)60,122Purchase of treasury stock(24,934)(3,243)Cash flows from financing activities:(24,934)(3,243)Cash flows from financing activities:(28,7074)39,564Cash and cash equivalents(29,777)513,354Cash flows from financing activities(28,7074)39,564Cash						
Depreciation and amorization19,24817,337Impairment of long-lived assets13Realized loss on sale of long-lived assets551Change in derivative instruments, net(536)(390)Effect of change in exchange rate on marketable securities and bank deposits(39)(4,288)Deferred income taxes, net(11,129)(6,3877)(Increase) in inventories, net(2,154)(16,454)Decrease (increase) in other receivables, income tax receivables, prepaid expenses and other(19,973)(11,962)(Decrease) increase in rade, income tax, accured expenses and other payables(7,734)2,579(Decrease) increase in rade, income tax, accured expenses and other payables(9,121)(14,210)(Investment in other intangible ascurities bonds, net(199,956)(5,285)Cash flows from investing activities:(120)(117)Purchase of plant, property & equipment, net(17,161)60,122Net cash (used in) provided by investing activities(24,934)(3,243)Cash flows from financing activities:(24,934)(3,243)Purchase of treasury stock(24,934)(3,243)Effect of exchange rate changes on cash and cash equivalents(287,074)39,564Cash and cash equivalents at end of period\$318,103\$Cash and cash equivalents(287,074)39,564Cash and cash equivalents(287,074)39,564Cash and cash equivalents(287,074)39,564Cash and cash equivalents at end of period\$ <th></th> <th>\$</th> <th>30,862</th> <th>\$</th> <th>(371,858)</th>		\$	30,862	\$	(371,858)	
Impairment of long-lived assets13Realized loss on sale of long-lived assets551Change in derivative instruments, net(536)(390)Effect of change in exchange rate on marketable securities and bank deposits(39)(4,288)Deferred income taxes, net11,1296,395Increase in inventories, net(21,54)(16,454)Decrease (increase) in other receivables, income tax receivables, prepaid expenses and other10,973(11,962)(Decrease) increase in trade, income tax, accrued expenses and other payables270,482405,233Expense from amorization of marketable securities bonds, net7,7342,579Net cash used in operating activities:(199,956)(5,285)Cash flows from investing activities:(120)(117)Investment in other intangible assets(120)(117)Investment in other intangible assets(120)(117)Investment in short-term bank deposits, net(35,573)-(Investment in other intangible assets(120)(117)Investment in short-term bank deposits, net(24,934)(3,243)Cash flows from financing activities:(24,934)(3,243)Purchase of treasury stock(24,934)(3,243)Cash and cash equivalents(209)2,297Decrease in cash and cash equivalents(287,074)39,564Cash and cash equivalents at end of period\$318,103\$Cash and cash equivalents at end of period\$318,103\$Cash Received during the y						
Relitzed loss on sale of long-lived assets551Change in derivative instruments, net(536)(390)Effect of change in exchange rate on marketable securities and bank deposits(39)(4,288)Deferred income taxes, net(11,129)(6,395)Increase in inventories, net(21,54)(16,454)Decrease in inventories, net(27,482)405,233Expense from amorization of marketable securities bonds, net7,7342,579Net cash used in operating activities:(11,29)(11,220)Purchase of plant, property & equipment, net(9,121)(11,4210)Investment in other intangible assets(120)(117)Investment in other intangible assets(120)(11,121)Investment in proceeds from marketable securities, net(11,161)60,122Net cash (used in) provided by investing activities(24,934)(3,243)Net cash used in financing activities:(24,934)(3,243)Net cash used in financing activities:(28,97)(28,97)Operase in trease in cash and cash equivalents(28,977)39,564Cash Bair Morenty stock(28,977)39,564Cash and cash equivalents at end of period\$ 318,103\$ 552,918Cash Paid during the year for:(23,51)\$ 4,093Income taxes\$ 2,351\$ 4,093Non-cash investing transactions:\$ 2,351\$ 4,093Non-cash investing transactions:\$ 7,63\$ 4,535Purchase of property, plant and equipment included in accounts payable\$ 7,63 <td< td=""><td></td><td></td><td>19,248</td><td></td><td>17,337</td></td<>			19,248		17,337	
Change in derivative instruments, net(536)(330)Effect of change in exchange rate on marketable securities and bank deposits(39)(4,288)Deferred income taxes, net(11,129)(6,395)Increase in inventories, net(2,154)(16,454)Decrease (increase) in other receivables, income tax receivables, prepaid expenses and other(2,0,973)(11,962)(Decrease) increase in trade, income tax, accrued expenses and other payables(270,482)405,233Expense from amortization of marketable securities bonds, net7,7342,579Net cash used in operating activities:(199,956)(5,285)Cash flows from investing activities:(120)(117)Investment in other intangible assets(120)(117)Investment in proceeds from marketable securities, net(17,161)60,122Net cash (used in) provided by investing activities(24,934)(3,243)Durbase of treasury stock(24,934)(3,243)Net cash used in financing activities(209)2,297(Decrease) increase in cash and cash equivalents(209)2,297(Decrease) increase in cash and cash equivalents(209)2,297(Decrease) increase in cash and cash equivalents(28,074)39,564Cash and cash equivalents at end of period§318,103§Cash and cash equivalents at end of period§318,103§Cash and cash equivalents at end of period§318,103§Cash Received during the year for:Income taxes\$2,351\$ </td <td></td> <td></td> <td></td> <td></td> <td>—</td>					—	
Effect of change in exchange rate on marketable securities and bank deposits(39)(4,288)Deferred income taxes, net15,003(31,877)(Increase) decrease in trade receivables, net(2,154)(16,454)Decrease (increase) in other receivables, income tax receivables, prepaid expenses and other(0,973)(11,929)(Decrease) increase in inventories, net(2,70,462)405,233Expense from amortization of marketable securities bonds, net7,7342,579Net cash used in operating activities:(199,956)(5,285)Purchase of plant, property & equipment, net(10,121)(14,210)Investment in other intangible assets(10,975)(11,122)Investment in other intangible assets(11,121)60,122Net cash (used in) provided by investing activities:(24,934)(3,243)Purchase of treasury stock(24,934)(3,243)Set for treasury stock(24,934)(3,243)Effect of exchange rate changes on cash and cash equivalents(209)2,297(Decrease) increase in cash and cash equivalents(209)2,297(Decrease) increase in cash and cash equivalents(28,074)39,564Cash Paid during the year for:(23,51)\$Income taxes\$5,667\$Cash Paid during the year for:\$\$Income taxes\$\$5,667Set for the treasury stock\$\$Non-cash linexcing:\$\$\$Non-cash investing transactions:\$\$Purchase						
Deferred income taxes, net15,003(31,877)(Increase) decrease in trade receivables, net(11,129)6,395Increase in inventories, net(2,154)(16,454)Decreases (increase) in other receivables, income tax receivables, prepaid expenses and other10,973(11,962)(Decrease) increase in trade, income tax, accrued expenses and other payables(270,482)405,233(Decrease) increase in trade, income tax, accrued expenses and other payables(270,482)405,233(Threase of plant, property & equipment, net(9,121)(14,210)Investment in other intangible assets(120)(117)Investment in other intangible assets(120)(117)Investment in other intangible assets(17,161)60,122Vet cash (used in) provided by investing activities(24,934)(3,243)Net cash used in financing activities(249)(3,243)Effect of exchange rate changes on cash and cash equivalents(209)2,297(Decrease) increase in cash and cash equivalents(209)2,297(Decrease) increase in cash and cash equivalents(207,77)33,554Cash Received during the year for:\$318,103\$Income taxes\$5,667\$24,169Cash Received during the gent for:\$\$34,993Purchase of property, plant and equipment included in accounts payable\$7,733Purchase of property, plant and equipment included in accounts payable\$55Purchase of property, plant and equipment included in accounts			, ,		· · ·	
(Increase) decrease in trade receivables, net $(11,129)$ $6,395$ Increase in inventories, net $(2,154)$ $(16,454)$ Decrease (increase) in other receivables, income tax receivables, prepaid expenses and other $(2,70,482)$ $405,233$ Expense from amortization of marketable securities bonds, net $7,734$ $2,579$ Net cash used in operating activities: $(19,9956)$ $(5,285)$ Purchase of plant, property & equipment, net $(120)$ $(11,20)$ Investment in other intangible assets $(120)$ $(117)$ Investment in short-term bank deposits, net $(27,642)$ $45,733$ (Investment in) proceeds from marketable securities, net $(17,161)$ $(60,122)$ Net cash (used in) provided by investing activities $(24,934)$ $(3,243)$ Cash flows from financing activities $(24,934)$ $(3,243)$ Effect of exchange rate changes on cash and cash equivalents $(209)$ $2,297$ (Decrease) increase in cash and cash equivalents $(227,074)$ $39,564$ Cash and cash equivalents $(227,074)$ $39,564$ Cash and cash equivalents at beginning of period $5$ $318,103$ $5$ Cash and cash equivalents at equivalents $(2,70,74)$ $39,564$ Cash Received during the year for: $1000000000000000000000000000000000000$	Effect of change in exchange rate on marketable securities and bank deposits					
Increase in inventories, net $(2,154)$ $(16,454)$ Decrease (increase) in other receivables, income tax, accrued expenses and other $10,973$ $(11,962)$ (Decrease) (increase in trade, income tax, accrued expenses and other payables $2(70,482)$ $405,233$ Expense from amorization of marketable securities bonds, net $7,734$ $2,579$ Net cash used in operating activities: $(199,956)$ $(5,285)$ Cash flows from investing activities: $(199,956)$ $(120)$ $(117)$ Investment in other intangible assets $(120)$ $(117)$ Investment in short-term bank deposits, net $(35,573)$ $-$ (Investment in provided by investing activities $(61,975)$ $45,795$ Cash flows from financing activities: $(24,934)$ $(3,243)$ Purchase of treasury stock $(24,934)$ $(3,243)$ Net cash used in financing activities $(287,074)$ $39,564$ Cash and cash equivalents $(200)$ $2,297$ (Decrease) increase in cash and cash equivalents $(287,074)$ $39,564$ Cash and cash equivalents $(287,074)$ $39,564$ Cash and cash equivalents $(287,074)$ $39,564$ Cash and cash equivalents $(287,074)$ $33,554$ Cash and cash equivalents $(287,074)$ $39,564$ Cash and cash equivalents $(287,074)$ $33,564$ Cash			,			
Decrease (increase) in other receivables, income tax receivables, prepaid expenses and other (Decrease) increase in trade, income tax, acrued expenses and other payables10,973(11,962) (270,482)(Decrease) increase in trade, income tax, acrued expenses and other payables(270,482)405,233Expense from amortization of marketable securities bonds, net7,7342,579Net cash used in operating activities:(199,956)(5,285)Purchase of plant, property & equipment, net(9,121)(14,210)Investment in short-term bank deposits, net(17,161)60,122Net cash (used in) provided by investing activities(61,975)45,795Cash flows from financing activities:(24,934)(3,243)Purchase of treasury stock(24,934)(3,243)Net cash used in financing activities(209)2,297Cash and cash equivalents(209)2,297(Decrease) increase in cash and cash equivalents(209)2,297(Decrease) increase in cash and cash equivalents(200)2,297(Decrease) increase in cash and cash equivalents(200)2,297(Decrease) increase in cash and cash equivalents(207,074)39,564Cash and cash equivalents at beginning of period5318,1035Cash Paid during the year for: Income taxes\$2,351\$Non-cash investing transactions: Purchase of property, plant and equipment included in accounts payable\$763\$Purchase of property, plant and equipment included in accounts payable\$55659 <td>(Increase) decrease in trade receivables, net</td> <td></td> <td>(11,129)</td> <td></td> <td></td>	(Increase) decrease in trade receivables, net		(11,129)			
(Decrease) increase in trade, income tax, accrued expenses and other payables $(270,482)$ $405,233$ Expense from amortization of marketable securities bonds, net $7,734$ $2,579$ Net cash used in operating activities $(199,956)$ $(5,285)$ Cash flows from investing activities: $(9,121)$ $(14,210)$ Purchase of plant, property & equipment, net $(120)$ $(117)$ Investment in other intangible assets $(120)$ $(117)$ Investment in proceeds from marketable securities, net $(17,161)$ $60,122$ Net cash (used in) provided by investing activities $(24,934)$ $(3,243)$ Purchase of treasury stock $(24,934)$ $(3,243)$ Net cash used in financing activities $(299)$ $2,297$ (Decrease) increase in cash and cash equivalents $(287,074)$ $39,564$ Cash and cash equivalents at beginning of period $5$ $318,103$ $8$ Cash and cash equivalents at of of period $5$ $318,103$ $8$ Cash Paid during the year for: Income taxes $5$ $2,667$ $5$ $24,169$ Cash Received during the year for: Income taxes $5$ $5,667$ $5$ $24,169$ Non-cash investing transactions: Purchase of property, plant and equipment included in accounts payable $5$ $763$ $5$ $403$ Non-cash investing transactions: Purchase of marketable securities, net $5$ $-559$ $559$ Purchase of marketable securities, net $5$ $-550$ $559$	Increase in inventories, net					
Expense from amortization of marketable securities bonds, net7,7342,579Net cash used in operating activities(199,956)(5,285)Cash flows from investing activities:(9,121)(14,210)Purchase of plant, property & equipment, net(9,121)(14,210)Investment in other intangible assets(120)(117)Investment in short-term bank deposits, net(35,573)(Investment in) proceeds from marketable securities, net(17,161)60,122Net cash (used in) provided by investing activities(24,934)(3,243)Purchase of treasury stock(24,934)(3,243)Net cash used in financing activities(249,34)(3,243)Purchase of treasury stock(249,34)(3,243)Cash and cash equivalents(287,074)39,564Cash and cash equivalents(287,074)39,564Cash and cash equivalents at beginning of period $605,177$ 513,354Cash and cash equivalents at end of period\$ 318,103\$ 552,918Cash Received during the year for: Income taxes\$ 2,351\$ 4,093Non-cash investing transactions: Purchase of property, plant and equipment included in accounts payable\$ 763\$ 453 8Non-cash financing transactions: Purchase of treasury stock\$\$ 559Purchase of treasury stock\$\$ 559			10,973			
Net cash used in operating activities(199,956)(5,285)Cash flows from investing activities:(9,121)(14,210)Purchase of plant, property & equipment, net(120)(117)Investment in other intangible assets(120)(117)Investment in proveds from marketable securities, net(17,161)60,122Net cash (used in) provided by investing activities(17,161)60,122Net cash (used in) provided by investing activities:(24,934)(3,243)Purchase of treasury stock(24,934)(3,243)Net cash used in financing activities(209)2,297(Decrease) increase in cash and cash equivalents(287,074)39,564Cash and cash equivalents at beginning of period\$ 318,103\$ 552,918Cash Paid during the year for: $s$ $s$ $s$ Income taxes\$ 2,351\$ 4,093Non-cash investing transactions: $s$ $s$ $s$ Purchase of preparty, plant and equipment included in accounts payable $s$ $s$ $s$ Non-cash investing transactions: $s$ $s$ $s$ $s$ Purchase of treasury stock $s$ $s$ $s$ $s$ Non-cash investing transactions: $s$ $s$ $s$ $s$ Purchase of treasury stock $s$ $s$ $s$ $s$ Purchase of treasury stock $s$ $s$ $s$ $s$ Purchase of treasury stock $s$ $s$ $s$ $s$ Non-cash investing transactions: $s$ $s$ $s$ $s$ <			(270,482)		405,233	
Cash flows from investing activities:Purchase of plant, property & equipment, netInvestment in other intangible assets(120)Investment in short-term bank deposits, net(120)(117)Investment in proceeds from marketable securities, netNet cash (used in) provided by investing activitiesCash flows from financing activities:Purchase of treasury stockNet cash used in financing activitiesPurchase of treasury stock(24,934)(3,243)Net cash used in financing activitiesPurchase of treasury stock(24,934)(24,934)(3,243)Effect of exchange rate changes on cash and cash equivalents(209)(27,074)39,564Cash and cash equivalents(209)(27,074)39,564Cash and cash equivalents(217,774)39,564Cash and cash equivalents(23,177513,354Cash and cash equivalents(24,934)(3,243)Cash and cash equivalents(209)(2,297(Decrease) increase in cash and cash equivalents(209)(27,074)39,564Cash and cash equivalents at end of periodSCash Paid during the year for:Income taxesNon-cash investing transactions:Purchase of property, plant and equipment included in accounts payableNon-cash financing transactions:Purchase of reasury stock<	Expense from amortization of marketable securities bonds, net		7,734		2,579	
Purchase of plant, property & equipment, net $(9,121)$ $(14,210)$ Investment in other intangible assets $(120)$ $(117)$ Investment in other intangible assets $(35,573)$ $$ (Investment in) proceeds from marketable securities, net $(17,161)$ $60,122$ Net cash (used in) provided by investing activities $(61,975)$ $45,795$ Cash flows from financing activities: $(24,934)$ $(3,243)$ Purchase of treasury stock $(24,934)$ $(3,243)$ Net cash used in financing activities $(24,934)$ $(3,243)$ Effect of exchange rate changes on cash and cash equivalents $(287,074)$ $39,554$ Cash and cash equivalents at beginning of period $605,177$ $513,354$ Cash and cash equivalents at do f period $$$$ $$$$ $$$$ Cash Paid during the year for:Income taxes $$$$ $$$$ Income taxes $$$$ $$$$ $$$$ $$$$ Non-cash investing transactions: $$$$ $$$$ $$$$ Purchase of property, plant and equipment included in accounts payable $$$$ $$$$ $$$$ Non-cash of marketable securities, net $$$$ $$$$ $$$$ $$$$ Non-cash e of marketable securities, net $$$$ $$$$ $$$$ $$$$ Income taxes $$$$ $$$$ $$$$ $$$$ $$$$ Non-cash investing transactions: $$$$ $$$$ $$$$ $$$$ $$$$ Purchase of treasury stock $$$$ $$$$ $$$$ $$$$ $$$$ $$$$ Non-cash financing	Net cash used in operating activities		(199,956)		(5,285)	
Purchase of plant, property & equipment, net $(9,121)$ $(14,210)$ Investment in other intangible assets $(120)$ $(117)$ Investment in other intangible assets $(35,573)$ $$ (Investment in) proceeds from marketable securities, net $(17,161)$ $60,122$ Net cash (used in) provided by investing activities $(61,975)$ $45,795$ Cash flows from financing activities: $(24,934)$ $(3,243)$ Purchase of treasury stock $(24,934)$ $(3,243)$ Net cash used in financing activities $(24,934)$ $(3,243)$ Effect of exchange rate changes on cash and cash equivalents $(287,074)$ $39,554$ Cash and cash equivalents at beginning of period $605,177$ $513,354$ Cash and cash equivalents at do f period $$$$ $$$$ $$$$ Cash Paid during the year for:Income taxes $$$$ $$$$ Income taxes $$$$ $$$$ $$$$ $$$$ Non-cash investing transactions: $$$$ $$$$ $$$$ Purchase of property, plant and equipment included in accounts payable $$$$ $$$$ $$$$ Non-cash of marketable securities, net $$$$ $$$$ $$$$ $$$$ Non-cash e of marketable securities, net $$$$ $$$$ $$$$ $$$$ Income taxes $$$$ $$$$ $$$$ $$$$ $$$$ Non-cash investing transactions: $$$$ $$$$ $$$$ $$$$ $$$$ Purchase of treasury stock $$$$ $$$$ $$$$ $$$$ $$$$ $$$$ Non-cash financing						
Investment in other intangible assets(120)(117)Investment in short-term bank deposits, net(35,573)-(Investment in short-term bank deposits, net(17,161) $60,122$ Net cash (used in) provided by investing activities(61,975) $45,795$ Cash flows from financing activities:(24,934)(3,243)Purchase of treasury stock(24,934)(3,243)Net cash used in financing activities(24,934)(3,243)Effect of exchange rate changes on cash and cash equivalents(209) $2,297$ (Decrease) increase in cash and cash equivalents(209) $2,297$ (Decrease) increase in cash and cash equivalents(209) $2,297$ (Cash and cash equivalents at beginning of period $605,177$ $513,354$ Cash and cash equivalents at end of period\$ $318,103$ \$Cash Received during the year for:Income taxes\$ $2,251$ Income taxes\$ $5,667$ \$ $24,169$ Non-cash investing transactions:\$ $5,667$ \$ $453$ Purchase of property, plant and equipment included in accounts payable\$ $763$ \$ $453$ Non-cash financing transactions:\$ $-$559Purchase of marketable securities, net$-$559$	Cash flows from investing activities:					
Investment in short-term bank deposits, net(35,573)(Investment in) proceeds from marketable securities, net(17,161)60,122Net cash (used in) provided by investing activities(61,975)45,795Cash flows from financing activities:(24,934)(3,243)Purchase of treasury stock(24,934)(3,243)Net cash used in financing activities(209)2,297(Decrease) increase in cash and cash equivalents(209)2,297(Decrease) increase in cash and cash equivalents(287,074)39,564Cash and cash equivalents at beginning of period605,177513,354Cash and cash equivalents at end of period\$ 318,103\$ 552,918Cash Paid during the year for:Income taxes\$ 2,351\$ 4,093Non-cash investing transactions:\$ 763\$ 453Purchase of property, plant and equipment included in accounts payable\$ 763\$ 453Non-cash financing transactions:\$ 559\$ 559Purchase of marketable securities, net\$ 559\$ 559	Purchase of plant, property & equipment, net		(9,121)		(14,210)	
(Investment in) proceeds from marketable securities, net(17,161)60,122Net cash (used in) provided by investing activities(61,975)45,795Cash flows from financing activities:(24,934)(3,243)Purchase of treasury stock(24,934)(3,243)Net cash used in financing activities(24,934)(3,243)Effect of exchange rate changes on cash and cash equivalents(209)2,297(Decrease) increase in cash and cash equivalents(287,074)39,564Cash and cash equivalents at beginning of period605,177513,354Cash and cash equivalents at end of period\$ 318,103\$ 552,918Cash Paid during the year for:\$ \$ 5,667\$ 24,169Income taxes\$ \$ 2,351\$ 4,093Non-cash investing transactions:\$ 763\$ 453Purchase of property, plant and equipment included in accounts payable\$ 763\$ 453Non-cash financing transactions:\$ 5,59\$ 5,59Purchase of marketable securities, net\$ 5,59\$ 5,507	Investment in other intangible assets		(120)		(117)	
Net cash (used in) provided by investing activities(61,975)45,795Cash flows from financing activities: Purchase of treasury stock(24,934)(3,243)Net cash used in financing activities(24,934)(3,243)Effect of exchange rate changes on cash and cash equivalents (Decrease) increase in cash and cash equivalents(209)2,297(Decrease) increase in cash and cash equivalents Cash and cash equivalents at beginning of period(287,074)39,564Cash and cash equivalents at end of period5318,103\$552,918Cash Paid during the year for: Income taxes\$5,667\$24,169Cash Received during the year for: Income taxes\$\$5,667\$24,169Non-cash investing transactions: Purchase of property, plant and equipment included in accounts payable\$763\$453Non-cash financing transactions: Purchase of treasury stock\$5559\$559Purchase of marketable securities, net\$\$559\$580	Investment in short-term bank deposits, net		(35,573)			
Cash flows from financing activities: Purchase of treasury stock(24,934)(3,243)Net cash used in financing activities(24,934)(3,243)Effect of exchange rate changes on cash and cash equivalents(209)2,297(Decrease) increase in cash and cash equivalents(209)2,297(Decrease) increase in cash and cash equivalents(287,074)39,564Cash and cash equivalents at beginning of period605,177513,354Cash and cash equivalents at end of period\$ 318,103\$ 552,918Cash Paid during the year for: Income taxes\$ 2,351\$ 4,093Non-cash investing transactions: Purchase of property, plant and equipment included in accounts payable\$ 763\$ 453Non-cash financing transactions: Purchase of marketable securities, net\$ 5,59\$ 559Purchase of marketable securities, net\$ 5,59\$ 580			(17,161)		60,122	
Purchase of treasury stock(24,934)(3,243)Net cash used in financing activities(24,934)(3,243)Effect of exchange rate changes on cash and cash equivalents(209) $2,297$ (Decrease) increase in cash and cash equivalents(209) $2,297$ (Cash and cash equivalents at beginning of period(287,074)39,564Cash and cash equivalents at end of period $605,177$ $513,354$ Cash and cash equivalents at end of period $$$$ $318,103$ $$$$ Cash Paid during the year for:Income taxes $$$$$,667$$Income taxes$$$$,667$$$$Non-cash investing transactions:$$$$,667$$$$Purchase of property, plant and equipment included in accounts payable$$$$$$$$Non-cash financing transactions:$$$$$$$$$$Purchase of marketable securities, net$$$$$$$$$$S$$$$$$$$$$$$S$$$$$$$$$$$$Income taxes$$$$$$$$$$$$Purchase of property, plant and equipment included in accounts payable$$$$$$$$$$Purchase of marketable securities, net$$$$$$$$$$$$S$$$$$$$$$$$$$$$$Purchase of marketable securities, net$$<$	Net cash (used in) provided by investing activities		(61,975)		45,795	
Purchase of treasury stock(24,934)(3,243)Net cash used in financing activities(24,934)(3,243)Effect of exchange rate changes on cash and cash equivalents(209) $2,297$ (Decrease) increase in cash and cash equivalents(209) $2,297$ (Cash and cash equivalents at beginning of period(287,074)39,564Cash and cash equivalents at end of period $605,177$ $513,354$ Cash and cash equivalents at end of period $$$$ $318,103$ $$$$ Cash Paid during the year for:Income taxes $$$$$,667$$Income taxes$$$$,667$$$$Non-cash investing transactions:$$$$,667$$$$Purchase of property, plant and equipment included in accounts payable$$$$$$$$Non-cash financing transactions:$$$$$$$$$$Purchase of marketable securities, net$$$$$$$$$$S$$$$$$$$$$$$S$$$$$$$$$$$$Income taxes$$$$$$$$$$$$Purchase of property, plant and equipment included in accounts payable$$$$$$$$$$Purchase of marketable securities, net$$$$$$$$$$$$S$$$$$$$$$$$$$$$$Purchase of marketable securities, net$$<$	Cash flows from financing activities:					
Net cash used in financing activities(24,934)(3,243)Effect of exchange rate changes on cash and cash equivalents(209)2,297(Decrease) increase in cash and cash equivalents(287,074)39,564Cash and cash equivalents at beginning of period605,177513,354Cash and cash equivalents at end of period\$ 318,103\$ 552,918Cash Paid during the year for:			(24,934)		(3,243)	
(Decrease) increase in cash and cash equivalents $(287,074)$ $39,564$ Cash and cash equivalents at beginning of period $605,177$ $513,354$ Cash and cash equivalents at end of period $$$$ $318,103$ $$$$ Cash Paid during the year for: Income taxes $$$$ $5,667$ $$$$ $24,169$ Cash Received during the year for: Income taxes $$$$ $$$$ $$$$ $$$$ $$$$ Non-cash investing transactions: Purchase of property, plant and equipment included in accounts payable $$$$ $$$$ $$$$ $$$$ $$$$ Purchase of treasury stock Purchase of marketable securities, net $$$$ $$$$ $$$$ $$$$ $$$$ S $$$$ $$$$ $$$$ $$$$ $$$$ $$$$ S $$$ $$$$ $$$$ $$$$ $$$$ $$$$ Purchase of marketable securities, net $$$$ $$$$ $$$$ $$$$ $$$$ S $$$ $$$$ $$$$ $$$$ $$$$ $$$$ Output $$$$ $$$$ $$$$ $$$$ $$$$ $$$$ S $$$ $$$$ $$$$ $$$$ $$$$ $$$$ S $$$ $$$$ $$$$ $$$$ $$$$ $$$$ S $$$ $$$$ $$$$ $$$$ $$$$ $$$$$ S $$$ $$$$						
(Decrease) increase in cash and cash equivalents $(287,074)$ $39,564$ Cash and cash equivalents at beginning of period $605,177$ $513,354$ Cash and cash equivalents at end of period $\$$ $318,103$ $\$$ Cash Paid during the year for: Income taxes $\$$ $5,667$ $\$$ $24,169$ Cash Received during the year for: Income taxes $\$$ $$2,351$ $\$$ $4,093$ Non-cash investing transactions: Purchase of property, plant and equipment included in accounts payable $\$$ $763$ $\$$ $453$ Non-cash financing transactions: Purchase of marketable securities, net $\$$ $$ $\$$ $559$ Purchase of marketable securities, net $\$$ $$ $\$$ $550$	Effect of exchange rate changes on cash and cash equivalents		(209)		2 297	
Cash and cash equivalents at beginning of period $605,177$ $513,354$ Cash and cash equivalents at end of period $$$ $318,103$ $$$ $552,918$ Cash Paid during the year for: $$$ $$,667$ $$$ $24,169$ Income taxes $$$ $$,667$ $$$ $24,169$ Cash Received during the year for: $$$ $$,667$ $$$ $$24,169$ Income taxes $$$ $$2,351$ $$$ $$4,093$ Non-cash investing transactions: $$$ $763$ $$$ $$453$ Purchase of property, plant and equipment included in accounts payable $$$ $763$ $$$ $$453$ Non-cash financing transactions: $$$ $ $$ $$559$ Purchase of marketable securities, net $$$ $ $$ $$559$ Such as e of marketable securities, net $$$ $ $$ $$580$						
Cash and cash equivalents at end of period\$ 318,103\$ 552,918Cash Paid during the year for: Income taxes\$ 5,667\$ 24,169Cash Received during the year for: Income taxes\$ 2,351\$ 4,093Non-cash investing transactions: Purchase of property, plant and equipment included in accounts payable\$ 763\$ 453Non-cash financing transactions: Purchase of treasury stock\$ \$ 559\$ 559Purchase of marketable securities, net\$ \$ 580\$ 559						
Cash Paid during the year for:Income taxes\$ 5,667\$ 24,169Cash Received during the year for:\$ 2,351\$ 4,093Income taxes\$ 2,351\$ 4,093Non-cash investing transactions:\$ 763\$ 453Purchase of property, plant and equipment included in accounts payable\$ 763\$ 453Non-cash financing transactions:\$\$ 559Purchase of treasury stock\$\$ 559Purchase of marketable securities, net\$ 580		\$		\$		
Income taxes\$5,667\$24,169Cash Received during the year for:\$2,351\$4,093Income taxes\$2,351\$4,093Non-cash investing transactions:\$763\$453Purchase of property, plant and equipment included in accounts payable\$763\$453Non-cash financing transactions:\$\$559Purchase of treasury stock\$\$559Purchase of marketable securities, net\$\$580		Ψ	510,105	Ψ		
Cash Received during the year for:\$2,351\$4,093Income taxes\$2,351\$4,093Non-cash investing transactions:\$763\$453Purchase of property, plant and equipment included in accounts payable\$763\$453Non-cash financing transactions:\$\$559Purchase of treasury stock\$\$559Purchase of marketable securities, net\$\$580		<b>.</b>				
Income taxes\$2,351\$4,093Non-cash investing transactions:\$763\$453Purchase of property, plant and equipment included in accounts payable\$763\$453Non-cash financing transactions:Purchase of treasury stock\$\$559Purchase of marketable securities, net\$\$580	Income taxes	\$	5,667	\$	24,169	
Non-cash investing transactions:\$763\$453Purchase of property, plant and equipment included in accounts payable\$763\$453Non-cash financing transactions:Purchase of treasury stock\$—\$559Purchase of marketable securities, net\$—\$580	Cash Received during the year for:					
Purchase of property, plant and equipment included in accounts payable\$763\$453Non-cash financing transactions:Purchase of treasury stock\$—\$559Purchase of marketable securities, net\$—\$580	Income taxes	\$	2,351	\$	4,093	
Purchase of property, plant and equipment included in accounts payable\$763\$453Non-cash financing transactions:Purchase of treasury stock\$\$559Purchase of marketable securities, net\$\$580	Non-cash investing transactions:					
Non-cash financing transactions:Purchase of treasury stock\$ —Purchase of marketable securities, net\$ —\$ —\$ 559\$ —\$ 580		\$	763	\$	453	
Purchase of treasury stock\$\$559Purchase of marketable securities, net\$\$580			_			
Purchase of marketable securities, net\$\$580		\$		\$	559	
		¢	_	¢		
#####		Φ		Φ	000	
	<del>пппп</del>					

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: January 27, 2022

TARO PHARMACEUTICAL INDUSTRIES LTD.

By: Name: <u>/s/ Uday Baldota</u> Uday Baldota

Title: Chief Executive Officer and Director